However, initial results of IFN-α treatment of other B-cell neoplasms were far less impressive, since IFN could provide only palliative benefit in certain low-grade or early stage B-cell lymphomas, with complete remission and overall response of 10 and 48%, respectively [33, 35]. This evidence concerns the gene IFNA2 and B-cell non-Hodgkin lymphoma.